5 completed, 2 recruiting, 1 active not recruiting, 1 available. 5 Phase 2, 3 Phase 1, 2 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Recruiting 2, Terminated 1 |
| Phase 1 | 3 | Completed 3 |
| Not applicable | 2 | Completed 1, Unknown 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow MaaT Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer MaaT033 capsule, Cemiplimab, Cisplatin - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 162 | 2025-11-17 | 2026-04-03 |
| Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial) Pooled allogeneic fecal microbiotherapy, Placebo - Transplant Complication | Phase 2 | Recruiting | MaaT Pharma | 387 | 2023-10-31 | 2024-12-27 |
| Safety and Gut Microbiota Analysis of an Oral Microbiotherapy in Patients With Amyotrophic Lateral Sclerosis MaaT033 - Amyotrophic Lateral Sclerosis, ALS | Phase 1 | Completed | MaaT Pharma | 15 | 2023-06-08 | 2025-06-15 |
| MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients MaaT013 - Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD | Phase 3 | Active not recruiting | MaaT Pharma | 66 | 2022-03-25 | 2024-10-17 |
| Prospective Interventional Study Exploring the Microbiota Recolonization in SR-GvHD Patients Receiving MaaT013 Blood and stool sample collection - Intestinal GVHD, Steroid Refractory GVHD | Not applicable | Unknown | MaaT Pharma | 40 | 2021-10-06 | 2023-10-11 |
| Safety and Tolerability Evaluation of MaaT033 MaaT033 capsule - Hematologic Diseases, Chemotherapy Effect | Phase 1 | Completed | MaaT Pharma | 21 | 2020-10-20 | 2022-04-12 |
| Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSfer fecal microbiota transfer - Fecal Microbiota Transplantation | Phase 2 | Completed | MaaT Pharma | 24 | 2018-08-13 | 2021-02-23 |
| Evaluation of Heterologous Fecal microbiotA Transfer in ICU Patients: a FeasibilitY and SafetY StudY fecal microbiota transfer - Intensive Care Units, Fecal Microbiota Transplantation | Phase 2 | Terminated | MaaT Pharma | 8 | 2018-01-15 | 2019-03-08 |
| InterventiOnal Study of Bone and Joint Infections Related Gut dysbiosIS Biological samples collection of blood and feces - Bone and Joint Infection | Not applicable | Completed | MaaT Pharma | 62 | 2016-12-01 | 2018-04-05 |
| PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients Autologous Fecal Microbiota Transplantation - Leukemia, Myeloid, Acute | Phase 1 / Phase 2 | Completed | MaaT Pharma | 20 | 2016-06-01 | 2020-09-09 |
| Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease MaaT013 - Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD | Available | MaaT Pharma | 2024-08-28 |
Amyotrophic Lateral Sclerosis (1) · Carcinoma, Non-Small-Cell Lung (1) · Hematologic Diseases (1) · Leukemia, Myeloid, Acute (1) · Neurodegenerative Diseases (1)
Fecal Microbiota Transplantation (2) · Bevacizumab (1) · Blood Specimen Collection (1) · Carboplatin (1) · Cisplatin (1) · Defecation (1) · Docetaxel (1) · Gemcitabine (1) · Paclitaxel (1) · Pemetrexed (1) · Vinorelbine (1) · cemiplimab (1)
France (11) · Belgium (3) · Germany (3) · Italy (3) · Spain (3) · Austria (2) · Canada (1) · Netherlands (1) · Poland (1) · Switzerland (1) · United Kingdom (1)
Florent Malard, MD, PhD (3) · Anahita Rouze (1) · Christian Recher, Pr (1) · Gaelle Bruneteau, MD, PhD (1) · Mohamad Mohty, MD, PhD (1) · Sarah Guenounou, MD (1) · Tristan Ferry, MD, PhD (1)